3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Stomach Neoplasms
5
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Pancreatic Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Sarcoma, Ewing
1
SCLC
1
Retinoblastoma
1
Osteosarcoma
1
Oligometastatic Disease
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Lymphoma
1
Locally Advanced Resectable Rectal Cancer
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Interventions
Doxorubicin
3
Methotrexate
2
Cisplatin
2
merphos
1
cabozantinib
1
apatinib
1
Zoledronic Acid
1
X-Rays
1
Triptorelin Pamoate
1
Surgical Procedures, Operative
1
Platinum
1
Phantoms, Imaging
1
Magnetic Resonance Spectroscopy
1
Ifosfamide
1
Drug Therapy
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Osteosarcoma
×
Drug Therapy
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled